Keynote Speakers MipTec 2009

 

  • Gregory T. Lucier
    The impact of deep sequencing on drug discovery and development
    In human genetic, a “second genomics” revolution has come into pass due to next-generation sequencing. An overview of this technique and of the information potential to be gained from it will be given during this lecture.
    Life Technologies
    Tuesday, October 13, 2009
    Chairman and CEO, Carlsbad, CA, US
    Curriculum vitae
   
  • Dr. Martin Mackay, Ph.D.
    R&D - As if our lives depended on it
    Today’s life science companies have talent, tools and technologies to transform physical health and economic prosperity.  In his lecture, Dr. Mackay will describe an industry urgently evolving to crack the attrition problem and meet ever-increasing demands for faster, safer, more effective and affordable medicines.
    Pfizer
    Wednesday, October 14, 2009
    Global PGRD Executive, New York, NY, US
    Curriculum vitae
   
  • Joint Keynote Speaker MipTec and Life Sciences Week
    Dr. Hans Clevers
    Wnt, Lgr5 stem cells and colon cancer
    The Wnt signaling pathway is of crucial importance to the biology of normal adult stem cells. Its deregulation is the principle cause of many cancers, most notably of the intestine. One of the genes that is controlled by the Wnt pathway encodes the Lgr5 surface receptor, an exquisite stem cell marker. Using a variety of genetic mouse models for Lgr5, new types of stem cells from a variety of tissues have been identified, isolated and cultured.
    Hubrecht Institute
    Tuesday, October 13, 2009
    Director, Utrecht, NL
    Curriculum vitae
   
  • Prof. Jürgen Drews
    Drug discovery: historical and current perspectives
    After briefly discussing the history of drug discovery, an attempt will be made to analyze the status quo of this field. Scientific strategies, which have been successful will be confronted with less successful ones. A case is made for an organizational climate characterized by curiosity, intellectual freedom, scientific rigor and an overall commitment towards the improvement of medicine above all other values.
    Thursday, October 15, 2009
    Chairman of the Board of Directors of GPC-Biotech AG, München. Deputy Chairman of  the Board of Directors of Morphosys AG, München and Member of the Board or Directors of Human Genome Sciences, Rockville, MD, USA
    Curriculum vitae